- Briefing Your roundup of Asian tech and startup news that matter
Aditya Hadi Pratama · · 1 min readTemasek’s deeptech arm leads $5m seed round of Singapore biotech startup
Allozymes, a Singapore-based synthetic biotech startup, announced it has raised US$5 million in its seed round.
More funding details
- Lead investor: Xora Innovation, the deep science investment arm of Temasek Holdings
- Other investors: SOSV, TI Platform Management, and Entrepreneur First
- Stage: Seed
More company updates
- The company will use the fresh funds to establish its manufacturing and business infrastructure.
- According to Allozymes, it will prioritize strong demand in the Southeast Asian market and the Asia Pacific.
-
Allozymes’ proprietary platform can analyze and maps millions of enzyme variants per day. It can also generate larger datasets than competitors, the company claims, and has the potential to become the largest enzyme data library.
- Founded in 2019 by Peyman Salehian and Akbar Vahidi, two scientists from the National University of Singapore, the company has done pilot projects with pharmaceutical, agrifood, and personal care companies.
For more coverage of the company, head here. You can also click on the link below to view key details about the company as well as its funding history.
Editing by Miguel Cordon and Jaclyn Tiu
(And yes, we’re serious about ethics and transparency. More information here.)
Stay updated on the go with our mobile app.
Get latest insights with smoother, more personalized experience through TIA mobile app.
